# RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma

> **NCT07445022** · PHASE4 · RECRUITING · sponsor: **Fudan University** · enrollment: 110 (estimated)

## Conditions studied

- Melanoma Advanced

## Interventions

- **DRUG:** tunlametinib

## Key facts

- **NCT ID:** NCT07445022
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-28
- **Primary completion:** 2028-09-30
- **Final completion:** 2029-01-31
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07445022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07445022, "RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07445022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*